HLA-DR
T cells
basic immunology
biologics
clinical immunology
food allergy
immune tolerance
immunotherapy and tolerance induction
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
revised:
14
07
2024
received:
14
02
2024
accepted:
05
08
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
18
9
2024
Statut:
aheadofprint
Résumé
Omalizumab (XOLAIR®)-assisted multi-food oral immunotherapy (mOIT) has been shown to safely, effectively, and rapidly desensitize patients with multiple food allergies. In our clinical trial (NCT02626611) on omalizumab-assisted mOIT, different desensitization outcomes (success or failure of desensitization) were observed following a period of either continued or discontinued mOIT. However, the association between the immunological changes induced by omalizumab-assisted mOIT and desensitization outcomes has not yet been fully elucidated. In this study, due to the key roles of regulatory T (Treg) cells and the type 2 helper T cell (Th2) pathway in immune tolerance to food allergens, we aimed to characterize their association with the desensitization outcomes of omalizumab-assisted mOIT. Mass cytometry and multiplex cytokine assays were performed on blood samples obtained from participants with allergies to peanut, cashew, or milk in our phase 2 clinical study (NCT02626611). Comprehensive statistical and bioinformatic analyses were conducted on high-dimensional cytometry-based single-cell data and high-throughput multiplex cytokine data. Our results demonstrated that the frequency of HLA-DR We demonstrated that the frequency of HLA-DR
Sections du résumé
BACKGROUND
BACKGROUND
Omalizumab (XOLAIR®)-assisted multi-food oral immunotherapy (mOIT) has been shown to safely, effectively, and rapidly desensitize patients with multiple food allergies. In our clinical trial (NCT02626611) on omalizumab-assisted mOIT, different desensitization outcomes (success or failure of desensitization) were observed following a period of either continued or discontinued mOIT. However, the association between the immunological changes induced by omalizumab-assisted mOIT and desensitization outcomes has not yet been fully elucidated. In this study, due to the key roles of regulatory T (Treg) cells and the type 2 helper T cell (Th2) pathway in immune tolerance to food allergens, we aimed to characterize their association with the desensitization outcomes of omalizumab-assisted mOIT.
METHODS
METHODS
Mass cytometry and multiplex cytokine assays were performed on blood samples obtained from participants with allergies to peanut, cashew, or milk in our phase 2 clinical study (NCT02626611). Comprehensive statistical and bioinformatic analyses were conducted on high-dimensional cytometry-based single-cell data and high-throughput multiplex cytokine data.
RESULTS
RESULTS
Our results demonstrated that the frequency of HLA-DR
CONCLUSIONS
CONCLUSIONS
We demonstrated that the frequency of HLA-DR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Sean N. Parker Center for Allergy and Asthma Research at Stanford University
Organisme : NIH HHS
Pays : United States
Organisme : Hartman Family Foundation
Organisme : Sunshine foundation
Organisme : Bezos Foundation
Informations de copyright
© 2024 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 2019;2(1):e185630.
Gupta RS, Warren CM, Smith BM, et al. The public health impact of parent‐reported childhood food allergies in the United States. Pediatrics. 2018;142(6):e20181235.
Warren CM, Aktas ON, Manalo LJ, Bartell TR, Gupta RS. The epidemiology of multifood allergy in the United States: a population‐based study. Ann Allergy Asthma Immunol. 2022;130(5):637‐648.e5.
Begin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7.
Labrosse R, Graham F, Des Roches A, Begin P. The use of omalizumab in food Oral immunotherapy. Arch Immunol Ther Exp. 2017;65(3):189‐199.
Andorf S, Manohar M, Dominguez T, et al. Observational long‐term follow‐up study of rapid food oral immunotherapy with omalizumab. Allergy Asthma Clin Immunol. 2017;13:51.
Andorf S, Purington N, Block WM, et al. Anti‐IgE treatment with oral immunotherapy in multifood allergic participants: a double‐blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85‐94.
Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using omalizumab‐facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. EClinicalMedicine. 2019;7:27‐38.
Manohar M, Dunham D, Gupta S, et al. Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab. Allergy. 2021;76(9):2809‐2826.
Syed A, Garcia MA, Lyu SC, et al. Peanut oral immunotherapy results in increased antigen‐induced regulatory T‐cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500‐510.
Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654‐660.
Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen‐responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med. 2004;199(12):1679‐1688.
Lozano‐Ojalvo D, Tyler SR, Aranda CJ, et al. Allergen recognition by specific effector Th2 cells enables IL‐2‐dependent activation of regulatory T‐cell responses in humans. Allergy. 2023;78(3):697‐713.
Weissler KA, Rasooly M, DiMaggio T, et al. Identification and analysis of peanut‐specific effector T and regulatory T cells in children allergic and tolerant to peanut. J Allergy Clin Immunol. 2018;141(5):1699‐1710.e1697.
Akdis CA. Allergy and hypersensitivity: mechanisms of allergic disease. Curr Opin Immunol. 2006;18(6):718‐726.
Sampson HA, O'Mahony L, Burks AW, Plaut M, Lack G, Akdis CA. Mechanisms of food allergy. J Allergy Clin Immunol. 2018;141(1):11‐19.
Wisniewski JA, Commins SP, Agrawal R, et al. Analysis of cytokine production by peanut‐reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy. Clin Exp Allergy. 2015;45(7):1201‐1213.
Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol. 2016;16(12):751‐765.
Chiang D, Chen X, Jones SM, et al. Single‐cell profiling of peanut‐responsive T cells in patients with peanut allergy reveals heterogeneous effector TH2 subsets. J Allergy Clin Immunol. 2018;141(6):2107‐2120.
Zhou X, Yu W, Lyu SC, et al. A positive feedback loop reinforces the allergic immune response in human peanut allergy. J Exp Med. 2021;218(7):e20201793.
Monian B, Tu AA, Ruiter B, et al. Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells. J Clin Invest. 2022;132(2):e20201793.
Bajzik V, DeBerg HA, Garabatos N, et al. Oral desensitization therapy for peanut allergy induces dynamic changes in peanut‐specific immune responses. Allergy. 2022;77(8):2534‐2548.
Ruiter B, Smith NP, Monian B, et al. Expansion of the CD4(+) effector T‐cell repertoire characterizes peanut‐allergic patients with heightened clinical sensitivity. J Allergy Clin Immunol. 2020;145(1):270‐282.
Wambre E, Bajzik V, DeLong JH, et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Sci Transl Med. 2017;9(401):eaam9171.
Boonpiyathad T, Sozener ZC, Akdis M, Akdis CA. The role of Treg cell subsets in allergic disease. Asian Pac J Allergy Immunol. 2020;38(3):139‐149.
Noval Rivas M, Chatila TA. Regulatory T cells in allergic diseases. J Allergy Clin Immunol. 2016;138(3):639‐652.
Lan F, Zhang N, Bachert C, Zhang L. Stability of regulatory T cells in T helper 2‐biased allergic airway diseases. Allergy. 2020;75(8):1918‐1926.
Geraldes L, Morgado J, Almeida A, et al. Expression patterns of HLA‐DR+ or HLA‐DR‐ on CD4+/CD25++/CD127low regulatory T cells in patients with allergy. J Investig Allergol Clin Immunol. 2010;20(3):201‐209.
Li DY, Xiong XZ. ICOS+ Tregs: a functional subset of Tregs in immune diseases. Front Immunol. 2020;11:2104.
Tan CL, Kuchroo JR, Sage PT, et al. PD‐1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med. 2021;218(1):e20182232.
Yang H, Ye S, Goswami S, et al. Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma. Int J Cancer. 2020;146(7):1993‐2006.
Luo Y, Xu C, Wang B, et al. Single‐cell transcriptomic analysis reveals disparate effector differentiation pathways in human Treg compartment. Nat Commun. 2021;12(1):3913.
Chaudhry A, Samstein RM, Treuting P, et al. Interleukin‐10 signaling in regulatory T cells is required for suppression of Th17 cell‐mediated inflammation. Immunity. 2011;34(4):566‐578.
Wei X, Zhang J, Gu Q, et al. Reciprocal expression of IL‐35 and IL‐10 defines two distinct effector Treg subsets that are required for maintenance of immune tolerance. Cell Rep. 2017;21(7):1853‐1869.
Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin‐10. Front Immunol. 2013;4:129.
Palomares O. The role of regulatory T cells in IgE‐mediated food allergy. J Investig Allergol Clin Immunol. 2013;23(6):371‐382.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775‐787.
Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523‐532.
Klein L, Khazaie K, von Boehmer H. In vivo dynamics of antigen‐specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA. 2003;100(15):8886‐8891.
Dang TD, Allen KJ, Martino D, Koplin JJ, Licciardi PV, Tang ML. Food‐allergic infants have impaired regulatory T‐cell responses following in vivo allergen exposure. Pediatr Allergy Immunol. 2016;27(1):35‐43.
Chen X, Oppenheim JJ. Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. Int Immunopharmacol. 2011;11(10):1489‐1496.
Schaier M, Seissler N, Becker LE, et al. The extent of HLA‐DR expression on HLA‐DR+ Tregs allows the identification of patients with clinically relevant borderline rejection. Transpl Int. 2013;26(3):290‐299.
Baecher‐Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol. 2006;176(8):4622‐4631.
Lopez‐Abente J, Benito‐Villalvilla C, Jaumont X, Pfister P, Tassinari P, Palomares O. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3+ Tregs. Eur Respir J. 2021;57(1):2000751.
Benito‐Villalvilla C, de la Rocha‐Munoz A, Lopez‐Abente J, et al. Ligelizumab impairs IgE‐binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN‐alpha production and FOXP3+ Treg generation. Allergy. 2023;78(4):1060‐1072.
Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin‐10 and transforming growth factor‐beta: the role of T regulatory cells. Immunology. 2006;117(4):433‐442.
Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL‐10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71‐109.
Qamar N, Fishbein AB, Erickson KA, et al. Naturally occurring tolerance acquisition to foods in previously allergic children is characterized by antigen specificity and associated with increased subsets of regulatory T cells. Clin Exp Allergy. 2015;45(11):1663‐1672.
Johnson‐Weaver BT, Sempowski GD, Staats HF. Nasal peanut + CpG immunotherapy enhances peanut‐specific IFN‐gamma in Th2 cells and IL‐10 in non‐Th2 cells in mice. Allergy. 2019;74(11):2220‐2223.
Matsuda M, Morie Y, Oze H, et al. Phenotype analyses of IL‐10‐producing Foxp3− CD4+ T cells increased by subcutaneous immunotherapy in allergic airway inflammation. Int Immunopharmacol. 2018;61:297‐305.
Akdis M, Akdis CA. Mechanisms of allergen‐specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621‐631.
Udemgba C, Lin A. B cells and food allergy. Curr Opin Pediatr. 2021;33(6):625‐632.
Thompson EA, Darrah PA, Foulds KE, et al. Monocytes acquire the ability to prime tissue‐resident T cells via IL‐10‐mediated TGF‐beta release. Cell Rep. 2019;28(5):1127‐1135.e1124.
Weissler KA, Frischmeyer‐Guerrerio PA. Genetic evidence for the role of transforming growth factor‐beta in atopic phenotypes. Curr Opin Immunol. 2019;60:54‐62.
Hsu P, Santner‐Nanan B, Hu M, et al. IL‐10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J Immunol. 2015;195(8):3665‐3674.
Neeland MR, Andorf S, Manohar M, et al. Mass cytometry reveals cellular fingerprint associated with IgE+ peanut tolerance and allergy in early life. Nat Commun. 2020;11(1):1091.